Navigation Links
Perceptive Informatics Enters License Agreement With EuroQoL Group to Provide Enhanced Standardization for ePRO Solution

BOSTON, Jan. 5 /PRNewswire-FirstCall/ -- Perceptive Informatics, the industry's leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (Nasdaq: PRXL), today announced that it has entered into a license agreement with the EuroQoL Group. The license allows Perceptive to provide EQ-5D, a standardized instrument to measure health-related quality of life outcomes, through its Electronic Patient Reported Outcomes (ePRO) solution in an Interactive Voice Response (IVR) format. Perceptive Informatics is among the first organizations in the industry to offer the EQ-5D instrument in an ePRO-IVR format.

The agreement provides clinical study sponsors the ability to collect health-related quality of life patient reported outcomes data via the telephone, using Perceptive's ePRO solution in an IVR format. With 83 official language versions of EQ-5D, the instrument can be used in a wide array of geographies for global clinical programs. EQ-5D is a non-disease specific instrument, making it applicable to a wide range of health conditions and treatments. The instrument allows for easy completion of required data by study participants. It provides a descriptive profile and a single index value for a particular health status.

"The use of electronic patient reported outcomes in clinical trials has grown rapidly, especially as ePRO data, which has been increasingly accepted by regulators, has expanded beyond efficacy data to include safety, inclusion/exclusion, and medication compliance data. As sponsors are now using ePRO for major therapeutic areas across phases of trials, our goal is to offer more value to clients in this important component of an overall eClinical platform," said Steve Kent, President of Perceptive Informatics. "We are pleased to incorporate EQ-5D into our ePRO solution, working with the EuroQoL Group to provide biopharmaceutical companies with this well-respected, widely used instrument and additional level of standardization."

"I believe that the availability of an IVR version of the EQ-5D is a significant breakthrough for the biopharmaceutical industry. As one of the most widely used standardized measures of health status in the world today, there are clear advantages to collecting EQ-5D data electronically. I expect that study sponsors, clinical researchers, and patients will be well served by this agreement between the EuroQoL Group and Perceptive since the IVR format provides a highly efficient option for EQ-5D data collection and database creation," said Stephen Joel Coons, Ph.D., Member of the EuroQoL Group and Professor of Pharmacy and Public Health at The University of Arizona.

Perceptive's ePRO solution in an IVR format offers an intuitive interface for capturing patient reported data, ranging from diaries and validated instruments, such as health-related quality of life questionnaires, to complex clinical assessments. Patients can use the Perceptive ePRO system by dialing a toll-free number where they access an application delivered in their own language. Applications are designed to facilitate rapid progression through questions, and responses can be entered easily by using a telephone key pad. Study sponsors and investigator sites can access ePRO data and diary compliance metrics in real time via an online web reporting capability. The ePRO solution has a rigorous clinical, linguistic, and systems validation in place.

About Perceptive Informatics

Perceptive Informatics, a subsidiary of PAREXEL, is the industry's leading eClinical solutions provider. Perceptive Informatics offers unprecedented access to innovative eClinical technologies and resources, providing clinical trial sponsors, CROs, and other service providers with the benefits of an extensive line of products and services throughout the entire clinical development lifecycle. In August, 2008 Perceptive was joined with ClinPhone plc, and the newly combined organization offers eClinical software and services that increase the efficiency and productivity of clinical research. Perceptive's expansive product portfolio includes Interactive Voice and Web Response Systems (IVRS/IWRS,) Medical Imaging, Electronic Data Capture (EDC) systems, Clinical Trial Management Systems (CTMS) and Electronic Patient Reported Outcomes (ePRO) solutions, as well as eClinical systems integration and implementation services. For more information about Perceptive Informatics, visit

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has over 9,180 employees. For more information about PAREXEL International visit

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2008 as filed with the SEC on November 7, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

    Jennifer Baird, Senior Director of Public Relations
    PAREXEL International
    Tel: +781-434-4409

    Rebecca Passo
    SHIFT Communications
    Tel: +617-681-1217
    Email :

SOURCE PAREXEL International Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Perceptive Informatics Improves Efficiency and Clinical Data Quality With Enhanced Version of EDC System
2. Perceptive Informatics Enhances Medical Imaging Capabilities for Assessment of Cardiac Function
3. Perceptive Informatics Improves Clinical Site Monitoring Access and Flexibility With Portable USB Drive Capability
4. BioInformatics, LLC Studies Effective Strategies for Scientific Publishing in a Web 2.0 World
5. White Paper Examines New Thin LIMS IT Implementation Strategy for cGMP Quality Informatics
6. DNA2.0 Launches New Website: Enhanced Design and Free Bioinformatics Tools Demonstrate DNA2.0's Customer Focus
7. BioInformatics, LLC Offers Solutions for Optimizing Service and/or Maintenance Contracts
8. Sigma-Aldrich Recognized by BioInformatics, LLC as Having the Most Useful and Easiest to Use Online and Print Catalogs
9. NorthPoint Domain and NYU Vascular Associates Partner to Develop New Generation of Care Delivery Informatics Instruments
10. Core Informatics Delivers Enterprise Core LIMS Installation to BioRelix Pharmaceuticals
11. IC Sciences Launches ICS Alliance to Advance Development and Adoption of Informatics Instruments for Next Generation Healthcare
Post Your Comments:
(Date:11/24/2015)... IN (PRWEB) , ... November 24, 2015 , ... The ... newest Special Interest Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent ... the last few years. Many AMA members have embraced this type of racing and ...
(Date:11/24/2015)... 24, 2015 --> ... report released by Transparency Market Research, the global non-invasive ... CAGR of 17.5% during the period between 2014 and ... Global Industry Analysis, Size, Volume, Share, Growth, Trends and ... testing market to reach a valuation of US$2.38 bn ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... the remaining 11,000 post-share consolidation (or 1,100,000 pre-share ... "Series B Warrants") subject to the previously disclosed ... 23, 2015, which will result in the issuance ... to the issuance of such shares, there will ...
(Date:11/24/2015)... ... November 24, 2015 , ... In harsh industrial processes, ... for in-line sensors can represent a weak spot where leaking process media is ... retractable sensor housings , which are designed to tolerate extreme process conditions. They ...
Breaking Biology Technology:
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... Oct. 29, 2015  The J. Craig Venter Institute ... "DNA Synthesis and Biosecurity: Lessons Learned and Options for ... Health and Human Services guidance for synthetic biology providers ... --> --> Synthetic ... the potential to pose unique biosecurity threats. It now ...
(Date:10/29/2015)... ARBOR, Mich. , Oct. 29, 2015 /PRNewswire/ ... Eurofins Genomics for U.S. distribution of its DNA ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq kit. ... to enable the preparation of NGS libraries for ... plasma for diagnostic and prognostic applications in cancer ...
Breaking Biology News(10 mins):